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 INTRODUCTION 
Guillain Barre Syndrome (GBS) or Acute Polyradiculoneuritis is 
an acute, diffuse post infective disorder of the nervous system involving 
the spinal roots, the peripheral nerves and occasionally the cranial nerves. 
The aetiology is thought to be widespread demyelination of the spinal 
roots and the peripheral nerves due to a cross reaction between myelin 
and unconfirmed agents like viruses. GBS is a syndrome of acute 
areflexic motor paralysis. The disorder is heterogeneous and diverse in its 
antecedent events, clinical presentations and natural course, such that 
making the diagnosis is a challenge for most neurologists. Although GBS 
often has a benign prognosis, 7% of patients die and further 16% suffer 
residual disability. The modalities of treatment of GBS are physiotherapy, 
supportive treatment, ventilator management, plasma exchange and of 
late intravenous immunoglobulins.                                    
This thesis was undertaken to study the clinical and 
epidemiological profile as well as electrophysiological features of 
Guillain Barre Syndrome and to know the incidence of various variants in 
the studied population. 
 
 AIM OF THE STUDY 
 
 To study the epidemiological features of GBS   
 To analyze the clinical profile of GBS 
 To evaluate electrophysiological features of GBS 
 To know about various G B variants in studied population 
 
 
 
 
 
 
REVIEW OF LITERATURE 
Guillain-Barré syndrome (GBS) is an acute, frequently severe, and 
fulminant polyradiculoneuropathy that is autoimmune in nature. It is the 
most common cause of acute or sub acute generalized paralysis in 
practice. (During certain past epochs it was exceeded in frequency by 
polio.)1 
Historical Background 
As with many other neurological syndromes, the understanding of 
G B syndrome has been shaped by the historic sequence of its description 
and contemporary developments in medicine  
Octave Landry is credited with the earliest description of what is 
now recognized as GBS. In 1859 he described a condition called 'acute 
ascending  paralysis'.7 
In 1916, G. Guillain, Barre, and Strohl - French army neurologists, 
reported on two soldiers who developed an acute paralysis associated 
with the loss of muscle stretch reflexes. They also described an elevation 
of CSF  
 
 protein with a normal cell count (albuminocytological 
dissociation). Andre Strohl was responsible for the electrophysiological 
aspects.1 
Landry's paralysis and Guillain Barre Syndrome were thought to be 
different entities (with a benign prognosis for GBS and an ominous 
prognosis for Landry's paralysis) till Haymaker and Kernohan in 1949,8 
exhaustively reviewed this debate and entitled their paper Landry-
Guillain-Barre syndrome implying that the two conditions are identical. 
Miller Fisher in 1956 observed a variant associated with 
ophthalmoplegia,ataxia, and areflexia.9 
 
EPIDEMIOLOGY: GBS occurs year-round at a rate of about 0.6-1.9 
cases/100,000 population. GBS occurs in all parts of the world and in all 
seasons, affecting children and adults of all ages and both sexes. Males 
are at 1.5-fold higher risk for GBS than females, and in western countries 
adults are more frequently affected than children. Slight increased 
frequency observed in Caucasians.1, 2, 5 
 
 
 
 Historical Background 
Year  Developments 
1834-
1837 
Earliest description of an afebrile generalized paralysis by  Wardrop 
and Ollivier 
1859 Landry's report of an acute, ascending, predominantly motor 
paralysis with respiratory failure leading to death 
1892  Osler's description of "febrile polyneuritis"; 
1916 The eponym “GBS” derives it’s name from the description by 
George Guillaine Barre and Strohl who performed the 
electrophysiological studies & CSF studies 
1949 The first comprehensive account of the pathology of GBS by 
Haymaker and Kernohan  
1969 
 
Asbury and colleagues established that the essential lesion was 
perivascular mononuclear inflammatory infiltration of the roots and 
nerves 
1975 Swine flu vaccination programme spurs interest  G B syndrome 
1978 Use of plasmaphresis in treatment reported by Brettle and coworker 
1990  NINCDS criteria for G B syndrome 
   
ETIOLOGY: A mild respiratory or gastrointestinal infection or 
immunization precedes the neuropathic symptoms by 1 to 3 weeks in 
approximately 60 percent of cases. Typical is a nondescript upper 
respiratory infection but almost every known febrile infection and 
immunization has at one time or another been reported to precede GBS . 
Respiratory infections are most frequently reported, followed by 
gastrointestinal infections 
In recent years, it has been appreciated from serologic studies that 
the enteric organism Campylobacter jejuni is the most frequent 
identifiable antecedent infection reported in up to 32% of cases. Clinical 
enteritis may be absent in 30% of C.jejuni associated GBS. In these cases 
there is only serologic evidence of the prior bacterial infection. Patients 
who develop GBS following an antecedent C jejuni infection often have a 
more severe course, with rapid progression , elevated anti-GM1 
antibodies, and a prolonged, incomplete recovery. A strong clinical 
association has been noted between C jejuni infections and the pure 
motor and axonal forms of GBS.18 
Other common antecedent events or associated illnesses include 
viral exanthems in children and numerous other viral illnesses in adults 
and children,6 particularly the large viruses of the herpes family 
(cytomegalovirus [CMV], Epstein-Barr virus [EBV].19 Cytomegalovirus 
(CMV) is the second most common antecedent infection with serologic 
evidence in up to 15% of cases a. CMV induced GBS tends to occur in 
younger patients and is often severe with respiratory failure, marked 
sensory and cranial nerve dysfunction, and elevated antibodies against 
ganglioside GM2.  Epstein Barr (EBV) infection may precede GBS in 
about 10% of cases; preceding clinical signs include mononucleosis, 
hepatitis, or pharyngitis.GBS may occur with HIV seroconversion.1, 2, 5                                
Other significant, although less frequently identified, infectious 
agents in GBS patients include Mycoplasma pneumoniae, Lyme disease, 
Haemophilus influenzae, para-influenza virus type 1, influenza A virus, 
influenza B virus, adenovirus, and herpes simplex virus have been 
demonstrated in patients with GBS .Hodgkin’s disease, lung cancer, 
thyroid disease, SLE, paraproteinemia, and sarcoidosis,surgery, trauma, 
and in the post-partum period. 
The administration of older-type rabies vaccine, prepared in 
nervous system tissue, is implicated as a trigger of GBS in developing 
countries where it is still used and A/New Jersey (swine) influenza 
vaccine was associated with a slight increase in the incidence of GBS. 
Cases are seen in temporal relationship to almost all other vaccinations, 
but the association in these instances seems idiosyncratic and infrequent.  
PATHOPHYSIOLOGY 
GBS is a post infectious, immune-mediated disease. It is likely that 
both cellular and humoral immune mechanisms contribute to tissue 
damage in AIDP. T cell activation is suggested by the finding that 
elevated levels of cytokines and cytokine receptors are present in serum 
[interleukin (IL) 2, soluble IL-2 receptor] and in cerebrospinal fluid. Most 
patients report an infectious illness in the weeks prior to the onset of 
GBS. Many of the identified infectious agents are thought to induce 
antibody production against specific gangliosides and glycolipids, such as 
GM1 and GD1b, 10 distributed throughout the myelin in the peripheral 
nervous system. The pathophysiologic mechanism of an antecedent 
illness and of GBS can be typified by    campylobacter jejuni infections. 
The virulence of C.jejuni is thought to be based on the presence of 
specific antigens in its capsule that are shared with nerves. Immune 
responses directed against the capsular components produce antibodies 
that cross-react with myelin to cause demyelination.11 Ganglioside GM1 
appears to cross-react with C jejuni lipopolysaccharide antigens, resulting 
in the immunologic damage to the peripheral nervous system. This 
process has been termed molecular mimicry.12 
Classic pathophysiological  studies of AIDP have demonstrated 
endoneurial perivascular mononuclear cell infiltration followed by 
macrophage – mediated ,multifocal stripping of myelin. This 
phenomenon results in defects in the propagation of electrical nerve 
impulses, with eventual; conduction block and flaccid paralysis.14-16In 
some patients with severe disease, a secondary consequence of the severe 
inflammation is axonal disruption and loss. A subgroup of patients may 
have a primary immune attack directly against nerve axons ,resulting in  a 
similar clinical  presentation.17,18 The  peripheral  nerves may be affected 
at all   levels from the roots to distal intramuscular  motor nerve findings, 
although the brunt of the lesions frequently falls on the ventral roots 
,proximal spinal nerves and cranial nerves20 
Principal Anti-Glycolipid Antibodies Implicated in Acute Immune 
Neuropathies11 
Clinical Presentation Antibody Target Usual Isotype 
Acute inflammatory 
demyelinating polyneuropathy 
(AIDP) 
No clear patterns 
GM1 most common 
IgG 
(polyclonal) 
Acute motor axonal 
neuropathy (AMAN) 
GD1a, GM1, GM1b, 
GalNAc–GD1a (<50% for 
any) 
IgG 
(polyclonal) 
Miller Fisher syndrome (MFS) GQ1b (>90%) IgG 
(polyclonal) 
Acute pharyngeal 
cervicobrachial neuropathy 
APCBN) 
GT1a  IgG 
(polyclonal) 
Source: Modified from HJ Willison, N Yuki: Brain 125:2591, 2002. 
CLINICAL MANIFESTATIONS 
GBS manifests as rapidly evolving areflexic motor paralysis with 
or without sensory disturbance. The usual pattern is an ascending 
paralysis that may be first noticed as rubbery legs. Weakness typically 
evolves over hours to a few days and is frequently accompanied by 
tingling dysesthesias in the extremities. The legs are usually more 
affected than the arms, the trunk, intercostal, neck, and cranial muscles 
may be affected later. Facial diparesis is present in 50% of affected 
individuals21, 22. The lower cranial nerves are also frequently involved, 
causing bulbar weakness with difficulty handling secretions and 
maintaining an airway; the diagnosis in these patients may initially be 
mistaken for brainstem ischemia23. Ophthalmoparesis may be observed in 
up to 25% of patients with GBS. Limitation of eye movement most 
commonly results from a symmetric palsy associated with cranial nerve 
VI. Ptosis from oculomotor nerve palsy also is often associated with 
limited eye movements Weakness progresses in approximately 5 percent 
of patients to total motor paralysis with respiratory failure within a few 
days24 . 
Pain in the neck, shoulder, back, or diffusely over the spine is also 
common in the early stages of GBS, occurring in ~50% of patients. These 
symptoms precede weakness and may be mistaken for lumbar disc 
disease, back strain, and orthopedic diseases. Deep tendon reflexes 
attenuate or disappear within the first few days of onset. Cutaneous 
sensory deficits (e.g., loss of pain and temperature sensation) are usually 
relatively mild, but functions subserved by large sensory fibers, such as 
deep tendon reflexes and proprioception, are more severely affected25, 26. 
Bladder dysfunction may occur in severe cases but is usually transient. If 
bladder dysfunction is a prominent feature and comes early in the course, 
diagnostic possibilities other than GBS should be considered, particularly 
spinal cord disease. Once clinical worsening stops and the patient reaches 
a plateau (almost always within 4 weeks of onset), further progression is 
unlikely. 
Autonomic involvement is common and may occur even in patients 
whose GBS is otherwise mild. Autonomic dysfunction of various degrees 
has been reported in 65% of patients admitted to the hospital. Its 
manifestations may be related to either increased or decreased 
sympathetic activity27. Signs of decreased sympathetic {orthostatic 
hypotension, anhidrosis) or decreased parasympathetic {urinary retention, 
gastrointestinal atony, or iridoplegia) function may be seen. Signs of 
excessive sympathetic activity include episodic or sustained hypertension, 
sinus tachycardia, tachyarrhythmias, episodic diaphoresis, and acral 
vasoconstriction. Excessive vagal activity accounts for sudden episodes 
of bradycardia, heart block, and asystole. These features require close 
monitoring and management and can be fatal. Urinary retention occurs in 
approximately 15 percent of patients soon after the onset of weakness, but 
catheterization is seldom required for more than a few days. 
Most patients require hospitalization, and almost 30% require 
ventilatory assistance at some time during the illness. Patients with 
weakness of neck muscles, tongue and palate often have concomitant 
diaphragmatic and respiratory muscle involvement. Patients requiring 
ventilator support have less favorable prognosis for neurologic recovery, 
have longer hospitalizations, and higher mortality. Fever and 
constitutional symptoms are absent at the onset and, if present, cast doubt 
on the diagnosis. Recovery usually begins 2-4 weeks after the progression 
ceases 
GBS VARIANTS: 
Several subtypes of GBS are recognized, as determined primarily 
by electro diagnostic and pathologic distinctions 3,4,29. 
ACUTE MOTOR AND SENSORY AXONAL NEUROPATHY 
(AMSAN): 
Initially  described by Feasby as axonal GBS. Characterized by 
acute quadriparesis, areflexia, distal sensory loss, and respiratory 
insufficiency.  CSF examination shows increased protein. Electro 
diagnosis shows loss of motor and sensory potentials with diffuse active 
denervation.  AMSAN leads to severe with quadriplegia, respiratory 
insufficiency and delayed, incomplete recovery30 
ACUTE MOTOR AXONAL NEUROPATHY (AMAN) :  
                     Originally described in patients from northern China, 
particularly children. It is characterized by acute/sub acute onset of 
relatively symmetric limb weakness, diffuse areflexia, facial and 
oropharyngeal muscle weakness, and respiratory insufficiency. Clinically 
presents as pure motor deficits30. Often associated with gastric enteritis 
due to C. jejuni with elevated anti-GM1 and anti-GD1a antibodies to C. 
jejuni. Electro diagnostic studies show evidence of motor axon loss 
sparing sensory Fibers without evidence of demyelination. Needle EMG 
shows diffuse denervation. CSF examination shows increased protein 
levels. 
 
MILLER-FISHER VARIANT: 
The Miller-Fisher syndrome, a common variant of GBS, is 
observed in about 5% of all GBS cases It is characterized by Classic triad 
of ophthalmoplegia, ataxia, and areflexia described by C. Miller Fisher in 
1956. Diplopia is the usual initial symptom, followed by limb or gait 
ataxia and areflexia. Abducens nerve palsy is the earliest lesion which 
may progress to complete ophthalmoplegia and ptosis, but pupillary 
reflex is spared. Ataxia is primarily noted during gait and in the trunk, 
with lesser involvement of the limbs. Motor strength is characteristically 
spared.Occasionally there may be mild sensory symptoms, swallowing 
difficulties, or proximal limb weakness in up to 1/3 or 1/2 of cases. The 
usual course is one of gradual and complete recovery over weeks or 
months. Although CSF protein is mildly elevated, it is less so than in 
typical GBS. Electro diagnosis shows loss of sensory potentials, with 
milder axonal degeneration. It clinically resembles brainstem 
inflammatory or ischemic disease. A close association exists between 
antiganglioside antibodies and the Fisher variant. Anti-GQ1b antibodies, 
triggered by certain C jejuni strains, have a relatively high specificity and 
sensitivity for the disease.6Dense concentrations of GQ1b ganglioside are 
found in the oculomotor, trochlear, and abducens nerves, which may 
explain the relationship between anti-GQ1b antibodies and 
ophthalmoplegia 
 
 PURE MOTOR VARIANTS:  
Acute, progressive, symmetric limb weakness, predominantly 
distal limb weakness,areflexia, without  sensory loss. Investigation shows  
elevated anti-GM1 titers due to preceding C. jejuni infection.  Course and 
recovery is similar to typical GBS. CSF protein is elevated. Electro 
diagnosis shows marked axonal degeneration with some accompanying 
demyelinating features. Differential diagnosis includes poliomyelitis, 
porphyria, acute fulminant, myasthenia gravis, tick paralysis. 
 
  
 PURE SENSORY VARIANTS: 
            A pure sensory variant of GBS has been described in the medical 
literature, typified by a rapid onset of large fiber sensory loss with 
resultant sensory ataxia and areflexia in a symmetric and widespread 
pattern. Sensory dysfunction may involve the face and torso in severe 
cases. Lumbar puncture studies show albuminocytologic dissociation in 
the cerebrospinal fluid (CSF), and electromyography (EMG) results show 
characteristic signs of a demyelinating process in the peripheral nerves. 
Prognosis is generally good, but immunotherapies, such as plasma 
exchange and the administration of intravenous immunoglobulin (IVIGs), 
can be tried in patients with severe disease or slow recovery. Differential 
diagnosis includes cervical myelopathy, malignant and nonmalignant 
sensory neuronopathy, Sjogren’s syndrome, ciguatera poisoning. 
 
PURE DYSAUTONOMIA VARIANT: 
Acute pandysautonomia without significant motor or sensory 
involvement is a rare presentation of GBS, first described by Young and 
coworkers, as a variant. Dysfunction of the sympathetic and 
parasympathetic systems results in severe postural hypotension, bowel 
and bladder retention, anhidrosis, decreased salivation and lacrimation, 
and pupillary abnormalities. About half of the patients have 
autoantibodies to ganglionic acetylcholine receptors which may play a 
pathogenetic role by blocking cholinergic transmission in autonomic 
ganglia. Routine Electro diagnosis studies are normal; autonomic testing 
such as heart rate variability, tilt-table testing, sympathetic skin 
responses, and sweat testing (QSART) may be abnormal. The condition 
characteristically progresses and then plateaus after few weeks. 50% of 
patients may recover slowly after several months. 
PHARYNGEAL-CERVICAL-BRACHIAL VARIANT: 
The pharyngeal-cervical-brachial variant is distinguished by 
isolated facial, oropharyngeal, cervical and upper limb weakness without 
lower limb involvement. (Ropper, 1986a). Ptosis, often with 
ophthalmoplegia, may be present. High titers to GT1a antibodies may 
present in few cases. CSF protein is elevated. Electro diagnostic studies 
may be normal, or show demyelinating changes in upper limbs. Recovery 
is delayed and, at times, incomplete. The differential diagnosis includes 
myasthenia gravis, diphtheria, and botulism and a lesion affecting the 
central portion of the cervical spinal cord and lower brainstem 
 
 
 PARAPARETIC VARIANT: 
It is a type of regional variant with isolated leg weakness and 
areflexia. Upper limbs, cranial nerves and sphincters are spared. 
Radicular pain commonly occurs in these patients. CSF shows elevated 
protein levels. Electro diagnosis shows demyelinating changes in lower 
limb nerves. MRI of spinal cord and lumbar roots is necessary to exclude 
lesion of distal cord and cauda equina 
OTHER LESS COMMON VARIANTS: 
Portions of the clinical picture frequently appear in isolated or 
abortive form and are a source of diagnostic confusion 
i. Acral paresthesias with diminished reflexes in either arms or legs. 
ii. Facial diplegia or abducens palsies with distal paresthesias  
iii. Isolated post infectious ophthalmoplegia. 
iv. Bilateral foot-drop with upper limb paresthesias. 
v. Acute ataxia without ophthalmoplegia. 
vi. Pure ophthalmoplegic form- associated with a specific anti-GQ1b 
antibody 
vii. GBS with severe bulbar and facial paralysis- associated with 
antecedent cytomegalovirus  infection and anti-GM2 
antibodies75 
viii. Acute polyneuritis cranialis not involving the first or second 
cranial nerves, may be a variant of GBS, when there is a 
monophasic illness with acute onset, raised CSF protein and 
recovery and no other cause is found 
Less difficulty attends the correct diagnosis of GBS if paresthesias in 
the acral extremities, progressive reduction or loss of reflexes and relative 
symmetry of weakness appear after several days. The laboratory tests, 
particularly nerve conduction studies that affirm the diagnosis of typical 
GBS, give similar but generally milder abnormalities if they are carefully 
sought in all these variant forms. In a few patients, the weakness 
continues to evolve for 3 to 4 weeks or longer. From this group, a chronic 
form of demyelinative neuropathy (CIDP) may emerge and an 
intermediate group that progresses for 4 to 8 weeks and then improves 
can be identified  
DIAGNOSIS: 
GBS is a descriptive entity. The diagnosis is made by recognizing 
the pattern of rapidly evolving paralysis with areflexia, absence of fever 
or other systemic symptoms, and characteristic antecedent events. Other 
disorders that may enter into the differential diagnosis include acute 
myelopathies (especially with prolonged back pain and sphincter 
disturbances); botulism (pupillary reactivity lost early); diphtheria (early 
oropharyngeal disturbances); Lyme polyradiculitis and other tick-borne 
paralyses; porphyria (abdominal pain, seizures, psychosis); vasculitic 
neuropathy (elevated erythrocyte sedimentation rate); poliomyelitis (fever 
and meningismus common); CMV polyradiculitis (in 
immunocompromised patients); critical illness neuropathy; 
neuromuscular disorders such as myasthenia gravis; poisonings with 
organophosphates, thallium, or arsenic; tick paralysis; paralytic shellfish 
poisoning; or severe hypophosphatemia (rare).  Laboratory tests are 
helpful primarily to exclude mimics of GBS.  
LABORATORY FINDINGS: 
The most important laboratory aids are the electro diagnostic 
studies and CSF examination.  
The CSF is often normal when symptoms have been present for 48 
h and by the end of the first week the level of protein is usually elevated 
with levels up to 100–1000 mg/dL, under normal pressure without 
accompanying pleocytosis. CSF protein level rises, reaching a peak in 4 
to 6 weeks and persisting at a variably elevated level for many weeks. 
The increase in CSF protein is probably a reflection of widespread 
inflammatory disease of the nerve roots, but high values have had no 
clinical or prognostic significance .In a few patients (fewer than 10 
percent), the CSF protein values remain normal throughout the illness. In 
10 percent of patients 10 to 50 cells per cubic millimeter, predominantly 
lymphocytes, may be found. Persistent pleocytosis suggests an alternative 
or additional process producing aseptic meningitis such as neoplastic 
infiltration, HIV, or Lyme infection. Both tau and 14-3-3 protein levels 
are reported to be elevated early (during the first few days of symptoms) 
in some cases of GBS. Tau increases in CSF may reflect axonal damage 
and predict a residual deficit. 
 
Abnormalities of nerve conduction are early and dependable 
diagnostic indicators of GBS4. They are diagnostic in 95% cases. Absent 
H-reflexes, delayed or absent or impersistent F waves, and low amplitude 
or absent SNAPs in the upper extremity combined with normal sural 
SNAPs are changes supportive of the diagnosis in the first week of 
illness. Typically, there is multifocal demyelination affecting proximal 
and distal nerve segments. Prolonged or absent F waves may be initial 
sole abnormality in about 30-50% of cases .Evidence of conduction block  
occurs in about 1/3 of cases; conduction slowing and temporal dispersion 
reflect demyelination. Prolonged distal latencies (reflecting distal 
conduction block) and absent F waves or prolonged F latency (indicating 
involvement of proximal parts of nerves and roots) are important 
diagnostic findings, all reflecting focal areas of demyelination.  
Most important predictor of recovery is the degree of axonal 
degeneration, best reflected by the amplitude of the compound muscle 
action potential. Motor potentials with amplitudes less than 20% normal 
suggest a prolonged, and often incomplete recovery.  
Needle EMG initially shows decreased motor unit recruitment. 
Subsequently with axonal degeneration fibrillation potentials appear 2—4 
weeks after onset.  
Electro diagnostic studies performed in the patients enrolled in the 
North American GBS Study found abnormalities of distal motor latencies 
and F-wave latencies in approximately one half of patients studied within 
30 days of onset. Partial motor conduction block (30%), slowing of motor 
conduction velocity (24%), and reduced distal CMAP amplitudes (20%) 
were less frequent.3, 4 
Lumbosacral spinal MRI may demonstrate gadolinium 
enhancement of lumbar roots in few cases. 
DIAGNOSTIC CRITERIA FOR GBS (Asbury And Cornblath) 35, 36  
I.  Features required for diagnosis  
a. Progressive motor weakness of more than one limb.   
b. Areflexia 
II. Features strongly supportive of the diagnosis  
a. Clinical features: 
i. Progression within four weeks 
ii. Relative symmetry of symptoms 
iii. Mild sensory symptoms or signs 
iv. Cranial nerve involvement 
v. Recovery within four weeks of progression  cessation 
vi. Autonomic dysfunction 
vii. Absence of fever at onset 
b. CSF picture: 
i. Raised CSF protein after 1 week of symptoms   
                          ii.Cell counts of less than or equal to 10 mononuclear  
                                    leucocytes per  cmm of CSF  
 
c. Electro diagnostic studies: 
i. Electro diagnostic features strongly supportive of the 
diagnosis (nerve conduction slowing or block)  
III. Features casting doubt on the diagnosis  
i. Pronounced persistent asymmetry of  weakness 
ii. Persistent bladder or bowel dysfunction 
iii. Bladder or bowel dysfunction at onset 
iv. More than 50 mononuclear leucocytes/3 mm 
v. Presence of polymorphonuclear leucocytes in CSF 
vi. Sharp sensory level 
IV. Features that rule out the diagnosis  
i. Current history of hexacarbon misuse 
ii. Abnormal porphyrin metabolism 
iii. Recent diphtheritic infection 
iv. Features clinically consistent with lead neuropathy 
v. Purely sensory syndrome 
vi. Definite diagnosis of poliomyelitis, botulism, 
hysterical paralysis, or toxic neuropathy 
 
 
 
ELECTRODIAGNOSTIC CRITERIA FOR GBS 3,4,77 
Electrophysiological classification of Guillain-Barre syndrome 
At least 3 sensory nerves and 3 motor nerves with multi-site 
stimulation F waves, and bilateral tibial H reflexes need to be evaluated. 
AIDP 
At least 1 of the following in each of at least 2 nerves, or at least 2 of 
the following in 1 nerve if all others inexcitable and distal compound 
muscle action potential (dCMAP) >10% lower limit of normal (LLN):  
• Motor conduction velocity <90% LLN (85% if dCMAP <50% 
LLN) 
• Distal motor latency >110% upper limit of normal (ULN) (>120% 
if dCMAP <100% LLN) 
• pCMAP/dCMAP ratio <0.5 and dCMAP >20% LLN 
• F-response latency >120% ULN. 
AMSAN 
• None of the features of AIDP except 1 demyelinating feature 
allowed in 1 nerve if dCMAP <10% LLN 
• Sensory action potential amplitudes less than LLN. 
AMAN 
• None of the features of AIDP except 1 demyelinating feature 
allowed in 1 nerve if dCMAP <10% LLN 
• Sensory action potential amplitudes normal. 
Inexcitable  
• dCMAP absent in all nerves or present in only 1 nerve with 
dCMAP <10%. 
TREATMENT: 
All patients with suspected GBS should be hospitalized for vigilant 
monitoring due to the high risk of respiratory failure and need for 
intubation and mechanical ventilation. Baseline spirometry, including 
FVC and oximetry, should be obtained. The cornerstone of treatment is 
that of meticulous general medical support. 
Very mild cases with only distal paresthesia and mild limb 
weakness may not need treatment, but it is advisable to wait 
approximately two weeks before concluding that there will be no further 
progression. Patients with vital capacities that are rapidly declining or 
below 18ml/kg or those with cardiovascular dysautonomia are 
appropriate candidates for observation in an ICU. 
The most important advances in treatment of GBS have been 
positive pressure ventilation and intensive respiratory and medical 
management in the ICU, both introduced during the European 
Poliomyelitis Epidemic of the 1950s. These have allowed patients with 
complications of immobilization and respiratory failure to survive and 
recover from paralysis. 
The criteria advocated for intuabation, weaning and extubation in GBS 
are: 
A. Intubation: 
i. Mechanical ventilatory failure with vital capacity (VC) of 12-15 
ml/kg.Falling VC over 4-6 hours or clinical signs of fatigue (brow 
sweating, tachycardia, and hyperpnoea) may prompt intubation at 
15ml/kg. 
ii.  PaO2 less than 70mmHg on inspired air. 
iii. Severe oropharyngeal paresis with difficulty in clearing secretions 
or repeated coughing and aspiration after swallowing. 
B. Weaning from ventilator: 
i. When VC exceeds 8-10 ml/kg with adequate oxygenation 
maintained with 35- 40% inspired oxygen. 
ii. Patient can voluntarily double resting minute volume. 
C. Extubation: 
1. When continuous positive airway pressure of 5-7 cm of 
water was tolerated without clinical signs of fatigue for 12-
24 hours. 
2. Arterial Pao2 greater than 9O mmHg on room air. 
3. Adequate alveolar ventilation. 
4. Improvement in bulbar paresis. 
Although many patients of GBS have clinical signs of fatigue of 
respiratory muscles, only 10% - 30% patients eventually require 
mechanical ventilation. Indications for intubation include an FVC 
dropping below 12ml/kg or in a normalized adult, FVC falling below 1 
liter patients who are subjectively dyspneic or appear to be struggling to 
breathe should be intubated, even if their FVC is above these levels. In 
general one should err on the side of early intubation than late. A simple 
bedside estimate of FVC can be made by having the patient count out 
loud. If the patient can take a maximal inspiration and then can count up 
to 25, the FVC is probably about 2 liters. A patient who can count up to 
10 probably has about 1 liter 
FVC. 
In patients with respiratory failure, the average duration of machine 
assisted respiration has been 50 days. In a study form India, 30% of the 
patients studied required mechanical ventilation. Weakness of facial, 
truncal, neck, bulbar and proximal weakness of upper limb and 
autonomic disturbances were predictors for need for subsequent 
mechanical ventilation. 
The prevention of nosocomial infections is another central feature 
of treatment, since 25% of patients acquire pneumonias and 30% acquire 
urinary infections. Prophylaxis for pulmonary embolism, adequate 
nutrition, and psychological care are the other major areas of concern in 
severe cases. As many as 30% of patients with GBS, experience 
significant pain early in their presentation. In adults pain tends to be in 
the paraspinal region. In children, pain may be more pronounced in the 
limbs. Conventional analgesics may be useful, in addition to those 
commonly used for treating neurogenic pain (such as tricyclic 
antidepressent medications). Alternatively, a brief course of high-dose 
corticosteroids can lead to marked improvement in pain control. 
IMMUNOTHERAPY OF GBS:  
Corticosteroids: 
For 50 years corticosteroids were the main stay of treatment for 
acute GBS on the basis of anecdotal experience, a few uncontrolled 
studies and the appeal of their anti-inflammatory effect40. 
Two randomized controlled trails, one using conventional doses of 
prednisolone for two weeks41 and the other, use high dose (500 mg) 
intravenous methylprednisolone 42 daily for 5 days have found no benefit. 
Steroids are thus no longer considered useful for GBS. 
Plasma Exchange: 
Evidence of the presence of antibodies43 or demyelinating serum 
factors has provided a rationale for use of plasma exchange in therapy of 
GBS.13 In 1978, Brettel et al44 first reported the benefits of plasma 
exchange in the treatment of GBS. Since then, several trials have been 
confirmatory. Three large trials - The North American GBS Study 
Group45, the French46  and the Swedish13 trials have established the 
benefit of plasma exchange. The conclusions derived from these three 
trials were: Plasma exchange is beneficial in acute GBS; it favorably 
modifies poor prognostic factors; maximum benefit is obtained when it is 
instituted early (within two weeks of illness) and not much benefit is 
expected after three weeks. 
In the usual regimen of plasma exchange, 21 a total of 200-250ml of 
plasma per kg body weight is removed in 4 - 6 treatments on alternate 
days. The time required to complete a series of exchanges is 8 - 14 days. 
Plasma as replacement fluid is not recommended 46 and now a days 
albumin or saline is used. The type of replacement fluid (albumin / saline) 
used in plasma exchange has not been found to influence the outcome 
Patients undergoing plasma exchange on continuous flow machine 
have a better outcome than on intermittent flow machines.33 Two 
continuous flow techniques can be used: Ultra filtration and 
centrifugation. In a recent study, no difference was found in terms of 
outcome between these two techniques.47 
Indications for starting plasma exchange in patients of GBS have 
been advocated by Mckhann and Griffin.48 These are: inability to walk 
unaided; rapid and significant reduction in serial vital capacity and onset 
of bulbar paralysis. The benefit of plasma exchange is diminished if 
treatment is begun after two weeks of illness but some patients still seem 
to benefit if their condition continued to worsen during third week. After 
an initial good response with plasma exchange, some patients may show 
deterioration necessitating further series of plasma exchange33, 34. 
Complications of plasma exchange49 may be related to the 
procedure (hypotension, volume overload), vascular access (venous 
thrombosis, pneumothorax with subclavian catheter), anti coagulation 
(bleeding tendencies with heparin, depletion of coagulation factors), 
replacement fluids (anaphylaxis with plasma usage) 39. Plasma exchange 
also has certain practical limitations like: availability of technical set up 
and trained personnel to carry out the procedure; greater risk for patients 
with cardiovascular complications or marked dysautonomia (associated 
with GBS) and small but real risk of transfer of infections (hepatitis and 
HIV) when plasma is used as replacement fluid38. 
Modified Plasma Exchange: 
A study from India50 showed that small volume plasma exchange 
(10 - 15ml/kg of plasma exchanged on consecutive days) during first two 
weeks of the illness showed results comparable to that of conventional 
plasma exchange (200 -250 ml/kg). A similar study report from Sri 
Lanka61 has supported this fact. All this was achieved at a lower cost and 
fewer complications which is important for widespread application in 
developing countries. The replacement fluid used in these studies was 
fresh frozen plasma. 
Immunoglobulins 
High dose intravenous immunoglobulin was first reported to be 
beneficial in GBS by Kleywey et al52 in 1988.Intravenous 
immunoglobulin has been found to be useful in treatment of many 
diseases with an autoimmune basis37. The proposed mechanisms53 for 
their action are: 
a. Passive transfer of neutralizing anti-idiotypic antibodies 
against auto antibodies. 
b. Intravenous immunoglobulin alters the structure and 
dynamics of the idiotypic network in the auto immune 
patient to regain physiological control of auto immunity. 
During the first week of illness, the preferred treatment for patients 
with GBS who have severe disease and require assistance to walk is 
either plasmapheresis or intravenous immunoglobulin. A controlled, 
randomized trial47 comparing intravenous immunoglobulin treatment with 
plasma exchange concluded that intravenous immunoglobulin was also 
effective as first line treatment. In this study, 52.7% of 74 patients 
receiving immunoglobulin compared with 34% of 73 patients undergoing 
plasma exchange had functional improvement of one grade or more after 
4 weeks. Although immunoglobulin was clearly more efficacious, this 
findings was challenged because response to plasma exchange in this 
study47 was inferior to that in earlier studies.45 This prompted a new 
multinational, multicentre trial54 that compared efficacy of 
immunoglobulin alone, plasmapheresis alone and plasmapheresis 
followed by immunoglobulin. After 4 weeks of treatment and 48 weeks 
of follow up, no statistically significant difference was seen between the 
treatments. Consequently the question of which therapy is preferable for 
using first considering their similar efficacy and cost is a matter of 
convenience and practicality.55 
The indications for immunoglobulin in GBS have not been clearly 
laid down yet. In the Dutch study trial, 47 inclusion criteria included acute 
GBS, inability to walk 10m independently and presentation within 2 
weeks of disease onset. If the illness continues to worsen in the first 15 
days despite a full course of plasma exchange, a trial of immunoglobulin 
therapy 55 is warranted. The dose recommended is 0.4g/kg/day for 5 days. 
Just like plasma exchange, the use of immunoglobulin has also been 
associated with treatment related fluctuations. 
Adverse reactions55 to immunoglobulin therapy are usually minor 
and occur in about 10% of patients. Side effects include fever, myalgia, 
headache, meningism, and eczema on hands. There is also an increased 
risk of thromboembolic events, as therapy with immunoglobulin 
increases serum viscosity. Anaphylaxis is very rare but potentially fatal. 
Immunoglobulin should be used with extreme caution in patients with 
renal failure which it may exacerbate. 
REHABILITATION: 
Rehabilitation requires an organized program with definite end 
points. There are no systematic studies of physiotherapy in GBS. But 
early goals include prevention of decubitus ulcers, tendon shortening, 
joint malalignment, peroneal nerve compression palsies and facilitation of 
pulmonary toilet. Psychological problems in form of depression, mental 
fatigue, impotence and those due to residual weakness should also be 
tackled. 
OUTCOME: 
Although GBS is often thought to have a benign prognosis, 7% of 
patients die and a further 16% suffer significant residual disability.66 
Speed of recovery varies and may take 6-8 months; no improvement is 
expected after 2 years.57 Remyelination is usually complete but recovery 
is poor when there has been Wallerian axonal degeneration 58 after which 
the axons regrow at 1mm per day so many do not reach their target 
muscles for several years if at all. 
The death rate has varied from 1.3% in different series with a mean 
of 6%, probably depending more on the quality of intensive care than 
specific treatments. Half of the deaths 58 are within first month - one third 
from cardiovascular autonomic complications such as asystole; a quarter 
from pneumonia or respiratory failure and the rest from pulmonary 
embolism, infection, infarction, renal failure and unrelated cause. 
With the currently available modalities of treatment, it is estimated 
that about 15% of GBS patients completely recover without any deficit 
and another 65% have persistent minor problems that generally do not 
impair conduct of everyday life.21 The disease in itself does not result in 
chronic fatigue but mild depression indicated by persistent mental fatigue 
is common. A few men have residual impotence. Three percent of 
patients may have one or more recurrence57 of the disease. 
COMPLICATIONS: 
The common complications of GBS include respiratory failure, 
atelectasis, aspiration, pneumonia, bladder dysfunction, pain, depression, 
phlebitis, pulmonary embolus and syndrome of inappropriate antidiuretic 
hormone secretion (SIADH) exacerbated by positive pressure ventilation. 
Pseudo tumor cerebri, papilloedema alone and unexplained seizures have 
been reported. 
Further complications from immobility and bed rest include 
decubitus ulcers secondary compression neuropathy such as ulnar 
neuropathy and peroneal neuropathy, and the psychiatric sequelae 
associated with a prolonged, immobilizing stay in the ICU. 
PROGNOSIS: 
Although the majority of patients with GBS make an acceptable 
functional recovery, a proportion succumb to the acute illness while 
others retain significant residual disability. It is thus important to be able 
to select only patients with a poor prognosis for treatment, which often 
involves discomfort, expense and risk of complications. No large-scale 
prospective study has ever been carried out and the available 
retrospective studies give an incomplete picture of outcome. It is also 
difficult to estimate how many patients remain disabled from literature. 
Hence a number of small studies have been conducted to correlate 
particular clinical features with a poor outcome. 
Osier and Sidell59 suggested that patients with a strictly motor 
neuropathy and no sphincter disturbances were more likely to have a 
benign prognosis. However Marshall60 described 37 patients including 
some with severe sensory loss or sphincter disturbance and could find no 
evidence that such features influenced outcome adversely. A particularly 
severe motor deficit appears to carry a greater risk of residual disability 
according to a number of authors.61 
Two pediatric 61,62 studies have suggested that the time taken to 
improve also has prognostic value. They concluded that an interval of 
greater than 18 days from maximum deficit to onset of improvement 
(plateau) was associated with incomplete recovery. Other factors 
common in the poor outcome group were absence of tendon reflexes from 
onset, severe weakness in distal muscles and a relatively low CSF 
protein. However majority of studies have failed to find any correlation 
between CSF protein and outcome. 
In a study by J.B. Winer et al,61 time taken to become bed bound, 
severity of peak deficit, need for assisted ventilation, age greater than 40, 
and small or absent compound muscle action potentials in the abductor 
pollicis brevis elicited by stimulating the median nerve, were found to be 
associated with poor outcome. However, time from onset of weakness 
until improvement began and duration of plateau phase, failed to show a 
significant correlation with outcome. This conclusion conflicts with 
previous observations56 in which failure to improve within 3 weeks of 
reaching peak deficit adversely affected outcome. In yet another study by 
NK Singh et al,63  rapid progression of illness, severe degree of paralysis 
and muscle wasting, prolonged period of peak paralysis lasting more than 
weeks, delayed onset of recovery not commencing within 3 weeks from 
onset of weakness, bulbar paralysis and respiratory involvement 
adversely affected outcome. Evidence of axonal damage in electro 
diagnostic studies was also associated with poor outcome. However age, 
sex, severity of sensory loss, sphincter disturbances, CSF findings and 
nerve conduction velocity did not significantly affect outcome. 
Autonomic dysfunctions were noticed in 66.6% cases but were mostly 
mild and transient, and did not affect long term outcome. Thus in 
summary, the following factors have been found to be associated with a 
higher probability of a poor prognosis. 
1. Etiology: Preceding diarrhea; Campylobacter jejuni infection; 
presence of GM1 antibodies. 
2. General severity: Severe, rapidly progressive disease peaking 
within 7 days from onset; greater maximum disability of arms/legs; 
early and prolonged (> 1 month) need for ventilatory support; 
reduced or inexcitable motor action potential amplitude (< 20% of 
lower limit of normal). 
3. Absence of immunomodulatory therapy. 
4. Poor repair: Old age (> 40 years); longer time until first 
improvement. However, gender, sensory involvement, sphincter 
disturbances, CSF protein, CSF cells, all have no effect on 
prognosis. Autonomic dysfunction is found to occur commonly but 
mostly mild and transient and does not affect long-term outcome. 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
50 patients diagnosed as Guillain Barre Syndrome (GBS) fulfilling 
the criteria as modified by Asbury, admitted in the Medical, Paediatric, 
Neurology wards of Government Rajaji Hospital from January 2009 to 
March 2011 were included in this study. 
Inclusion criteria: 
Patients fulfilling NINCDS criteria for GB syndrome (Asbury and 
Cornblath, 1990) and patients with clinical variants of GB syndrome. 
Exclusion criteria: 
Patients with equivocal diagnosis or inadequate clinical details or 
laboratory investigations were excluded 
Demographic and clinical profile 
              Patient’s data, type of antecedent event, interval between 
antecedent event and onset of neurological symptoms, seasonal trends, 
were recorded in a predesigned protocol (Appendix A).Detailed clinical 
examination findings, pattern of weakness and sensory and autonomic 
disturbances, presence of respiratory muscle weakness and requirement 
on ventilator assistance and mortality were documented. Variants were 
separated from typical GBS for analysis of clinical details. 
 
CSF analysis 
             Cerebrospinal fluid examination was done in all the patients. The 
protein level and cell count were looked for albumino cytological 
dissociation. 
Electrophysiological analysis 
Nerve conduction studies were performed using standard 
techniques. Motor NCS included stimulation of the median and ulnar 
nerves at the wrist and forearm while recording from the abductor pollicis 
brevis muscle and abductor digiti minimi muscle of the hand, 
respectively, and of the deep peroneal and posterior tibial nerves at the 
ankle and knee, while recording from the extensor digitorum brevis 
muscle and the abductor hallicus muscle, respectively. Supraclavicular 
stimulation was performed on one or more UE motor nerves, usually the 
ulnar nerve, in an attempt to identify conduction block or slowing 
proximal to the elbow. F waves were measured with each motor NCS for 
which a compound muscle action potential (CMAP) result was obtained. 
The H reflex was recorded from the gastrocnemius and soleus muscles 
after stimulation of the posterior tibial nerve. The CMAP amplitude, 
distal motor latency, motor nerve CVs, H reflex amplitude and latency, 
and shortest F response latencies were measured. Sensory NCS were 
performed, using antidromic techniques, on the median nerve, ulnar nerve 
and sural nerve. SNAP amplitude, latency; conduction velocity were 
noted 
The values were compared with reference values from our 
laboratory as well as according to Indian standards. Demyelinating 
neuropathy, axonal neuropathy and conduction block were defined as per 
criteria recommended by Alpers et al73 and Oh et al 
All patients were treated conservatively with physiotherapy and 
mechanical ventilatory assistance, where required. Patients who 
deteriorated in hospital and who could afford it, were treated with 
intravenous Immunoglobulin (0.4g/kg/for 5 days) and rest of the patients 
were treated with steroids i.e., intravenous methylprednisolone and 
plasmapheresis depending on availability of drug and affordability of the 
patient. Time taken to reach peak deficit, interval from maximum deficit 
to onset of improvement (plateau time), duration of ventilatory support 
required and nature of complications were noted. 
During each examination, the following were noted: 
1. Medical Research Council Grading of muscle weakness. 
0. No muscle contraction visible 
1. Flicker of contraction but no movement 
2 .Joint movement when effect of gravity eliminated 
3 .Movement against gravity but not against examiner's resistance 
4 .Movement against resistance but weaker than normal 
5 .Normal power 
2. Hughes Disability Grade (0 - 6) was noted according the 
following. 
0 - Healthy. 
1 - Minor symptoms or signs. 
2 - Able to walk 5m without assistance, walking frame, or stick but   
        unable to do manual work including housework, shopping or  
        gardening. 
3 - Able to walk 5m with assistance, walking frame, or stick. 
4 - Chair/bedbound. 
5 - Requiring assisted ventilation (for at least part of day or night). 
6 - Dead. 
3. Bedside Autonomic function tests - Resting Heart rate, Resting 
Blood Pressure, Postural Hypotension, Blood pressure changes at 
the end of one minute and 3 minutes on standing from lying 
position, wherever possible. In addition complaints suggestive of 
autonomic dysfunction such as excessive sweating, urinary 
retention and constipation, palpitations, postural giddiness were 
also noted. 
OBSERVATIONS AND RESULTS 
A total of 50 patients were studied. All patients were hospitalized 
and the average duration of hospital stay was 17.57 days. 
1. Age and Sex distribution: 
                         35 patients (70%) were males and 15(30%) were females. 
The age of patients ranged from 4 to 72 years (Mean age 36.72 years) 
with the maximum number (26%) of patients in between 51 to 60 yrs age 
group & in between 21 to 30 (20%) yrs (Table-1).                               
                                     Table 1. Age and sex distribution 
Sex 
Age  
<12 
12 – 
20 
21 – 
30 
31 – 
40 
41-50 51-60 >60 
M 4 1 5 6 3 12 4 
F 3 3 5 2 1 1 0 
Total 7 4 10 8 4 13 4 
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2. Seasonal incidence: 
                              Most number of cases were seen in the months of April 
to June. However no significant increased incidence in any particular 
season could be inferred. (Table-2). 
                                     
                                          Table 2. Seasonal incidence in GBS 
 
Months No. of cases Percentage 
Jan – March 10 20% 
April – June 18 36% 
July – September 12 24% 
Oct-December 10 20% 
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3. Antecedent illness: 
Twenty three (46%) patients had some antecedent event prior to the 
development of GBS (Table-3). The most common antecedent illness was 
lower respiratory tract infection. In patients with a history of preceding 
illness, the mean duration between onset of GBS and the preceding illness 
was 9.06 (± 4.21) days. 
                
                                             Table 3. Antecedent events 
 
Antecedent events No. of patients Percentage 
(%) 
Upper respiratory tract infection 4  8 
Diarrhea 4 8 
Post vaccination - - 
Lower Respiratory tract 
infection 
9 18 
Fever 6 12 
None 27 54 
 
 
 
 
CHART 3.    ANTECEDENT EVENTS 
 
 
                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           4. First Symptom of illness: 
The first symptom of the illness was in the form of motor weakness 
in 32 (64%) patients and it was sensory in the form of pain, paraesthesia 
or numbness in the remaining 18(36%) patients. Bulbar weakness was 
presenting symptom in 3 (6 %) patients and Ataxia in 1 patient. 
Table 4. First symptom 
Motor symptoms No. of patients Percentage 
Weakness of UL &LL ( P & D) 16 32 
Proximal weakness 9 18 
Distal Weakness  4 8 
Bulbar weakness 3 6 
Total 32 64 
 
Sensory symptoms No. of patients Percentage 
Paraesthesia 9 18 
Pain in back 3 6 
Numbness in legs 5 10 
Ataxia 1 2 
Total 18 36 
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CHART 4b .SENSORY SYMPTOMS 
 
                           
 
 
5. Mode of onset: 
Thirty patients (60%) had ascending form of paralysis. Only 4 
(8%) patients had descending type of paralysis (Table-5). Sixteen patients 
(32%) had simultaneous involvement of both proximal and distal 
muscles. 
Table 5. Mode of onset of GBS 
Mode No. of patients Percentage 
Ascending paralysis 30 60 
Descending paralysis 4 8 
Simultaneous involvement of all 4 limbs 16 32 
 
6. Progression to peak deficit: 
Twelve patients developed maximal deficit in 1 day, majority of 
patients (48%) developed peak deficit in 2 days.(Table-6). 
Table 6. Progression to peak deficit: 
DAY(S) No. of patients Percentage 
1 12 24 
2 24 48 
3 9 18 
4 4 8 
5 1 2 
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7. Maximal grades of disability: 
                                    Eight patients (16%) admitted with respiratory 
distress, Twenty four patients admitted in bed bound state .During the 
hospital stay, at peak deficit ,Seventeen patients (34%) developed 
respiratory distress and treated with ventilatory support .Thirty two 
(64%)patients developed bed bound state  during the hospital stay.  Three 
(6%) patients died. The cause of death was respiratory failure following 
aspiration pneumonia in 1 patient who had rapidly progressed disease. 
One of the patients, a 17 year old female who had a cardiac arrest, had 
severe autonomic dysfunction with fluctuating blood pressure and heart 
rate died on the day of admission itself. 
Table 7. Grade of disability (On admission & at peak) 
Grade On admission At peak 
No. of patients Percentage No. of patients Percentage 
6 - - - - 
5 8 16 17 34 
4 24 48 32 64 
3 15 30 1 2 
2 3 6 - - 
1 - - - - 
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8. Sensory Deficit: 
Objective sensory loss was elicited in only 7(14%) out of the 50 
patients. The sensory deficit was in the form of diminished vibration and 
joint position sense, which occurred in a glove and stocking distribution. 
9. Cranial Nerve Dysfunction: 
Twenty eight patients had cranial nerve dysfunction. Twenty seven 
(54%) patients had facial nerve palsy, among which three patients had 
unilateral facial nerve involvement which progressed to involve 
contralateral side also in due course. Nine patients had involvement of 9th 
and 10th cranial nerves. Total external ophthalmoplegia was observed in 
two patients. These patients also had severe ataxia, areflexia and 
weakness in the lower limbs. A diagnosis of Miller Fisher variant of GBS 
was made in them. One patient had left recurrent laryngeal nerve palsy. 
Table 8. Cranial nerve dysfunction 
Cranial Nerve Number of patients Percentage 
VII – Unilateral, Bilateral 27 54 
IX, X 9 18 
III, IV, VI 2 4 
    
10. Respiratory muscle weakness: 
Sixteen patients had respiratory muscle paralysis and treated with 
ventilatory support .The development of respiratory distress is monitored 
by periodic assessment of  maximal inspiratory force and expiratory vital 
capacity, development of neck muscle weakness, by observing single 
breath count . 
11. Autonomic dysfunction: 
Patients who were in Grade 4 disability or more were not subjected 
to standing blood pressure recordings. Only sitting blood pressures were 
recorded in these patients. In patients who were on ventilator, the 
spontaneous changes in heart rate and blood pressure were noted. 
Autonomic dysfunction was detected in 12 (24%) patients (Table.9). 
Table 9. Autonomic dysfunction 
Autonomic dysfunction Number of patients Percentage 
Cardiac  Arrhythmia 3 6 
Postural Hypotension 4 8 
Fluctuating B.P. 2 4 
Transient  Urinary retention 
&hesitancy 
3 6 
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12. Ataxia: 
Two patients who was diagnosed to have Miler-Fisher variant of 
GBS presented with ataxia. One patient who was admitted in bedridden 
state, on recovery showed ataxia which recovered subsequently 
13. Cerebrospinal Fluid (CSF) Analysis: 
CSF pressure was normal and CSF was clear in all patients. CSF 
glucose was also normal (approximately half the blood glucose level) in 
all patients. CSF protein concentration was raised above 50 mg% in 40 
(80%) patients at one week. CSF protein level was normal in 10 patients. 
Three patients had lymphocytic pleocytosis of 20, 30 and 40 cells/cmm. 
None of the remaining patients had CSF pleocytosis 
  
Table 10. CSF Protein level 
CSF Protein (mgms %) No. of patients Percentage 
< 45 10 20 
45 – 100  22 44 
100 – 150 15 30 
>150 3 6 
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14. Electrophysiological studies: 
Nerve conduction studies were conducted in all patients. Fifteen 
patients were found to have reduced motor conduction velocities 
consistent with demyelinating neuropathy. Nine patients were found to 
have decreased amplitude of action potentials consistent with axonal 
pattern of neuropathy. Twenty six patients had mixed pattern of 
neuropathy. These patients had both demyelinating features (prolonged 
distal latency, reduced conduction velocity) as well as axonopathy 
features (reduction of CMAP amplitude) 
 
                                  Table 11. Nerve conduction studies  
 
Type 
Number of 
patients 
Percentage 
Demyelinating 15 30 
Axonal 9 18 
Mixed 26 52 
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 15 .Motor conduction abnormalities 
Motor conduction studies of Median, Ulnar,Peroneal,Tibial nerves 
were done .Distal latency, distal CMAP amplitude, conduction velocity , 
H reflex amplitude and latency ,F wave latency were assessed. Varying 
degree of involvement in these nerves was observed, suggesting multi 
focal nature of the disease. The H reflex was absent in all cases. The 
electrophysiological study findings were completely normal, with the 
exception of absent H waves in 2 patients (4%) in the first week of 
disease onset.  
Table 12. Motor conduction abnormalities 
(Percentage of involved nerves) 
Nerve DL 
prolongation 
Distal 
amplitude 
reduction 
CV 
reduction
Conduction 
block 
Inexcitable 
nerves 
Median 62  80  68 26 10 
Ulnar 66 75 70 20 8 
Peroneal 76 66 72 30 26 
Tibial 78 68 76 32 20 
 
 
 
 16. Sensory conduction abnormalities 
Sensory conduction studies of Median, Ulnar,Sural nerves were 
done .distal latency, SNAP  amplitude, conduction velocity  were 
assessed. SNAP abnormalities commonly involved in upper limb nerves 
in the form of conduction velocity reduction and reduced amplitude.Sural 
nerve less commonly involved .Preservation of sural nerve SNAP 
confirms the acquired as well as demyelinating nature of the disease in 
most of the cases 
Table 13. Sensory conduction abnormalities 
(Percentage of involved nerves) 
 
Nerve CV reduction 
Reduced 
amplitude 
Absent SNAP 
Median 22 20 34 
Ulnar 26 28 22 
Sural 18 18 16 
                  CHART  12. MOTOR CONDUCTION 
ABNORMALITIES 
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CHART  13. SENSORY CONDUCTION ABNORMALITIES 
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17 .Complications: 
Aspiration pneumonia is the most common complication in the 
studied population. Aspiration pneumonia was observed more frequently 
in patients admitted with bulbar dysfunction .Septicemia occurred in one 
diabetic patient .Deep venous thrombosis occurred in one patient after 
prolonged immobilization for which he was treated with low molecular 
weight Heparin. Urinary tract infection was noted in one patient .E.Coli 
was grown on urine culture and treated with appropriate antibiotics  
                                
Table 14. Complications 
Complications 
Number of 
patients 
Percentage 
Aspiration 
pneumonia  
8 16 
Septicemia 1 2 
Urinary tract 
infection 
1 2 
DVT 1 2 
 
 
18. Treatment: 
All patients received physiotherapy and the sixteen patients who 
developed respiratory failure were put on mechanical ventilation. Two 
patients received intravenous immunoglobulins in addition to 
conservative therapy. Both of them showed good response with arrest of 
progression of muscular muscle weakness by 2 to 3 days. Forty five 
patients received intravenous methylprednisolone. Patients with 
intravenous steroids do not show much benefit over supportive treatment. 
Three patients who were admitted with minimal deficit did not receive 
steroids. 
Table 15. Various modalities of treatment 
Treatment Number of patients Percentage 
IV MP  45 90 
Plasma exchange - - 
IV IG 2 4 
No treatment 3 6 
 
 
 
 
  
 19. Mortality: 
Three patients (6%) died in this study. One patient developed 
aspiration pneumonia and later died due to septicemia and shock. One 
patient had fluctuating blood pressure and cardiac arrhythmia. She finally 
died due to cardiac arrest. One patient died of cardiac arrest while on 
ventilator. 
20. Duration of hospital stay: 
Patients were hospitalized and admitted in various medicine, 
paediatric wards. Patients who required ventilatory support were 
transferred to Intensive medical care unit and respiratory support was 
given. Average duration of hospital stay was 21.44    days .Maximum 
duration was 29 days in one patient. 
 
 
 
 
 
 
 
21. Disability on discharge: 
Disability after discharge was assessed according to Hughes’s 
scale. Most of the patients (64%) were discharged at Grade 3 (i.e. able to 
walk with support) .Twelve patients (24 %) were discharged at Grade 
2.Three patients recovered almost completely; they were discharged at 
grade 1. 
 
Table 16. Disability on discharge 
Grade No. of Patients Percentage 
6 3 6 
5 - - 
4 - - 
3 32 64 
2 12 24 
1 3 6 
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22. Incidence of subtypes & variants 
Of 50 cases of GBS ,acute inflammatory demyelinating neuropathy 
(AIDP) was the most common subtype forming 38 cases (76%) followed 
by Acute motor axonal neuropathy (AMAN)  .Acute Motor Sensory      
Axonal Neuropathy was observed in 2 (4%) patients. Miller – Fisher 
variant of GBS was observed in 2 young male patients. One patient 
presented with Cervico-brachial-pharyngeal variant.. 
                   
Table 17. GB syndrome variants 
Variants No. of 
patients 
Percentage 
AIDP 38 76 
AMAN 7 14 
AMSAN 2 4 
Miller-Fisher variant 2 4 
Cervico-brachial-pharyngeal 
variant 
1 2 
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 DISCUSSION 
A total of 50 patients were included in this prospective study. The 
maximum number of patients was in between 51 to 60 years age group 
(26%). Kaplan et al16 reviewed 2575 cases and found the peak incidence 
to be between 50 and 74 years of age with lesser peak between 15 and 35 
years. Similarly Peter C. Dowling65 also reported two peaks. In Thakaran 
et al50 series however, the mean age of study group was only 28 years.  
There is a male preponderance in our study which is in conformity 
with the report by Robert M. et al.66 However, Peter C. Dowlin’s65 study 
of 176 patients Showed an equal incidence in males and females. 
No seasonal variation in incidence of GBS could be inferred from 
this study in conformity with the majority of studies in literature66. 
However a few studies have noted a seasonal clustering of cases. Kaur et 
al67 reported an increased incidence in summer and autumn. Peter C. 
Dowling65 also noted an increase in summer. 
Twenty three (46%) of our patients had a definite antecedent event 
prior to onset of illness. Winer et al61 reported that over half of GBS 
patients experience symptoms of viral respiratory or gastrointestinal 
infections. Ropper et al also reported a high incidence of 73%. In contrast 
a study by Kaur et al67 showed a lower incidence of 32%. Zhahirul Islam 
et al showed 69% had antecedent illness of which 37% of cases were 
preceded by diarrhoea71. 
The interval between prodromal illness and onset of GBS is most 
frequently from 1-3 weeks. Occasionally it is as long as 6 weeks. Kaur et 
al67 reported a mean interval of 9.2 days. In our study there is a mean 
interval of 9.06 (± 4.21) days between the prodrome and the onset of 
GBS. The most common antecedent illness was lower respiratory tract 
infection (18%) while diarrhoeal illness and upper respiratory tract 
infection was seen in four patients (8%). 
Ascending paralysis was noted in 60% (30 patients) and 
descending paralysis in 8% (4 patients), while 32 %( 16 patients) had 
simultaneous involvement of all four limbs. According to description by 
Winer et al61 that muscle weakness usually starts in legs and ascends to 
arms in most cases. A metaanalysis of large series by Allan H. Ropper21 
showed ascending paralysis in 60%, descending paralysis in 20% and 
involvement of all four limbs simultaneously in 20% cases. 
In 32% patients, the first symptom of illness was motor in the form 
of flaccid paralysis of both upper and lower limbs, 34% had paraesthesia 
in hands and feet, numbness or pain, bulbar symptoms was present in 
6%of cases. One patient presented with ataxia. However Robert et al 
reported first symptom as sensory in 83% and motor in 17% of patients. 
Allan H. Ropper21 in his metaanalysis reported 85% incidence of 
paraesthesia. In a study by Winer et al61 75% patients had paraesthesia, 
Robert M, et al described 83% incidence in paraesthesia. Objective 
sensory loss occurred in 7 patients (14%) in the form of diminished 
touch, vibration and joint position sense which occurred in glove and 
stocking distribution. This is much lower than the 40% reported by Allan 
H. Ropper 21 in his metaanalysis. Winer et al 61 noted sensory loss in 52% 
of his patients. 
All patients had involvement of the legs and involvement of limbs 
was symmetric in all cases. None of the patients had involvement of 
hands alone, which is in conformity to the observation of Winer et al61 
who said that the arms are not affected in isolation. Two patients also had 
ataxia and involvement of 3rd, 4th and 6th cranial nerves. They were 
diagnosed to have Miller Fisher Variant of GBS. 
Respiratory failure was present in 32% of our patients. Allan 
H.Ropper 21 in his meta analysis showed that 10% of patients have 
respiratory failure. Winer et al61 noted a 23% incidence of respiratory 
failure. The average duration of mechanical ventilation in our patients 
was 9.12 days. 
Twenty four patients (48%) presented with bedridden state, eight 
patients(16%) presented with features of respiratory distress and 
immediately needed ventilator support ,seventeen patients (34%) reached 
grade V disability  and Thirty  two (64%) patients reached grade IV 
(bedridden state). In the study by Winer et al61 only 12% retained the 
ability to walk throughout the illness and the remaining 88% became 
bedridden. This is in contrast to the report by RDM Hadden et al58 who 
said 40% patients become bedbound. 
Overall, about 50% of patients with GBS reach maximal weakness 
by 1 week, 70% by 2 weeks, and 80% by 3 weeks in the course of 
illness61. In this study 24% of patients reached peak deficit within 1 day 
of onset of illness, 90% by 3 days. 
56% of our patients had cranial nerve dysfunction.20% of patients 
had involvement of multiple cranial nerves. This is in conformity with the 
50% incidence reported by Winer et al61 and 60% in Allan H. Ropper’s21 
meta analysis. Kaur et al67 reported an incidence of 41% in her study 
from North India. 
Facial Nerve was the most commonly involved 27 patients in our 
series in concordance with most series. IX and X cranial nerves were 
involved in only 9 patients in contrast to the reported incidence of 50% in 
Allan H. Ropper’s meta analysis.3,4,6 cranial nerves involved in 2 
patients. Other cranial nerves including recurrent laryngeal nerve was 
involved in 2 patients 
 
Autonomic dysfunction is reported to occur in up to 50% of GBS 
patients P.Hachenecker et al68 noted dysfunction in 69% of their patients. 
NK Singh et al63 documented 67% incidence. In this study autonomic 
dysfunction occurred in 24% of patients.  Cardiac arrhythmia occurred in 
6% of cases, postural hypotension in 8% of cases, Fluctuating Blood 
pressure was noted in 4% of patients. Transient sphincteric dysfunction in 
the form of urinary retention and hesitancy was seen in three (6%) 
patients. Allan H.Ropper’s meta analysis reported 15% incidence of 
transient bladder disturbances in GBS patients NK Singh et al63 observed 
sphincter disturbance in 20% of patients. 
CSF protein was raised above 50mg% in 40 patients.Winer et al61 
reported raised CSF protein in 80% patients while 90% was reported in 
Allan H.Ropper’s21 meta analysis. The lower number of patients with 
raised CSF protein in this study was probably because all CSF studies 
were done between 1 and 2 weeks from onset and not repeated thereafter. 
It is possible that there may have been a rise in CSF protein later in the 
course of illness, which was not recorded. Furthermore, it has been noted 
in some studies that CSF protein may not rise throughout the course of 
illness in some patients with GBS. Gupta RC63 reports such patients did 
not show rise in CSF protein even at 6 weeks. 
CSF pleocytosis was seen in three patients. CSF mononuclear cell 
counts of up to 50 per cmm may be seen in GBS and does not rule out 
diagnosis of GBS. 
Electrophysiological studies were conducted in all patients and 15 
of them showed demyelinating pattern, 9 of them showed axonal pattern, 
26 patients mixed pattern .Patients having mixed and axonal pattern 
showed poor prognosis compared to patients having demyelinating 
pattern. Two patients showed normal conduction study initially but repeat 
nerve conduction showed demyelinating pattern, and two patients initially 
had prolongation of f latency and absent H wave as the only feature and 
rest of the conduction were normal   , on repeat conduction after one 
week showed demyelinating pattern 
Many authors have found a proportion of patients to have normal 
nerve conduction and also involvement of nerves in varying severity. The 
population varies form 9% to 20%.70 and is higher in the first few weeks 
of illness. This multi focal involvement has been explained as due to   
 1) The patchy nature of pathology of GBS which means that 
studies confined to one or two nerves may miss abnormal findings. 2) 
Maximum conduction velocities may conceal abnormalities since 
conduction can occur normally in some fibres while being partially 
blocked in some others. 3) Lastly it is likely that proximal conduction 
blocks occur commonly in GBS that distal motor conduction would be 
unaffected76 
Three   patients died in this study. One patient developed aspiration 
pneumonia and later died due to Septicemia and shock. One patient had 
fluctuating blood pressure and cardiac arrhythmia and died due to cardiac 
arrest .one patient died due to cardiac arrest while on ventilator. 
Case fatality in this study was 6%. Mortality in GBS varies from 
1.3% to 13% in different series with a mean of about 6% Winer et al61 
reported 13% mortality in his study of 100 patients. NK Singh et al63 
noted 8% mortality. 
Total duration of hospital stay varied from 29 days to 16 days, 
average being 21.44 days. Most of the patients were being discharged at 
grade 3(64%), 24% cases discharged at grade 2, 6% cases were recovered 
almost completely from the illness.  
Of all GB syndrome variants AIDP subtype predominates which 
was demonstrated in various studies. In this study 38 patients (76%) 
diagnosed to have AIDP, 7 patients (14%) diagnosed to have AMAN,2 
patients  (4% ) diagnosed to have  AMSAN. Other variants like Miller-
Fisher variant was observed in 2 patients and Cervico pharyngeal  
brachial variant was observed in 1 patient. 
AIDP is the predominant subtype in United states and Europe (up 
to 90%) and axonal subtype predominates in china (70 % AMAN, 
25%AIDP,5% others) 73 .Hadden etal74 noted 71% 
AIDP,4%AMAN,2%AMSAN,1% Miller Fisher subtypes in his study. 
Zhahirul Islam71 et al showed AIDP in 82% cases and AMAN in 15% 
cases. Gupta et al noted AIDP in 70% cases, AMAN in 20% cases, Miller 
Fisher variant in 5 % cases72  in India. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY 
                                    In this prospective study of 50 patients with GBS 
(based on Asbury’s Criteria), it was found to be commonest in the age 
group above 50 years and there was a male preponderance. 
                                  Consistent with the known features of GBS, no 
significant seasonal predilection was present and 46% of the patients gave 
a history of a definite antecedent illness prior to the onset of GBS. The 
most common antecedent illness was lower respiratory tract infection 
seen in 18% of our patients followed by a non descript fever in 12%, 
followed by upper respiratory tract infection and gastro-intestinal illness  
                               Areflexic symmetric motor paralysis was the 
presenting feature of all the patients with the majority showing ascending 
type of paralysis (60%).The onset of GBS was heralded by both motor 
and sensory symptoms. Acute onset of flaccid weakness of both upper 
and lower limbs as well as predominant proximal weakness and sensory 
symptoms in the form of paraesthesiae confined to the fingers and toes 
were the common presentation. 
                               Thirty two (64%) reached bed bound state with 16 
patients (32%) required ventilatory support. Seventy two percent of 
patients reached maximal disability by 2 days, 90% by 3 days and 98 % 
by 4 days of onset of illness 
                                Autonomic dysfunction was seen in 24% of patients 
and was mostly mild and transient. However severe autonomic 
dysfunction was seen in one patient and was the cause of his death due to 
cardiac arrhythmia. Sphincter dysfunction in the form of urinary retention 
and hesitancy was transient, lasting 2 – 3 days and occurred in6 % of 
patients. 
                           Cranial nerve dysfunction occurred in 56% of patients 
with facial nerve being the commonest nerve involved (54%).20% of 
patients suffered with multiple cranial nerve palsies. 
                          Contrary to most reports, which state up to 40% objective 
sensory loss, we noted objective sensory loss in only 14% of our patients 
                         CSF protein was raised above 45mg% in most of the 
patients (80%), after 1 week of illness.CSF cell count showed reduced 
cell count demonstrating albumino cytological dissociation.CSF 
lymphocytic pleocytosis was seen in 3 patients. However, all 3 patients 
fell well within the modified Asbury’s criteria for diagnosis of GBS 
which states that a pleocytosis of up to 50 cells / cmm may be seen in 
patients of GBS. 
                           Electrophysiological studies conducted in all patients 
revealed demyelinating pattern in 15 patients, axonal pattern in 9 patients 
and mixed pattern in 26 patients.  
                          AIDP was the most common variant in studied 
population .Seven patients diagnosed to have AMAN variant, two 
patients diagnosed to have AMSAN variant. Two patients who are 
presented with ataxia later had ophthalmoparesis and diagnosed as having 
Miller Fisher variant .One case of Cervico-brachial-pharyngeal variant 
also evaluated in our study. 
                          Patients with AMSAN type developed muscle wasting 
later and had permanent disability after 3 months of follow up .All the 
three patients who died were diagnosed to have AIDP.But there is no 
definite correlation exists between the type of presentation with fatality 
and disability. 
 
 
 
 
 
 
 
 
 CONCLUSIONS 
1. GBS occurs in all age groups with a greater incidence in the older age 
group above 50 years. However age did not have any correlation with 
prognosis. 
2. GBS affects both sexes; however males were affected more than 
females in the ratio of    7:3 in this study. 
3. Nearly 1/2   of patients reported a definite antecedent event prior to 
onset of GBS. 
4. Onset of GBS is heralded by both motor and sensory symptoms 
However; objective sensory deficit is seen in very few patients. 
5. Ascending type of paralysis was most commonly seen in our study. 
6. Progression to maximal motor deficit occurred within 3 days in 90% of 
patients. Progression of muscle weakness beyond 4 weeks is not seen. 
7. Cranial nerve dysfunction occurred in 56% of patients in GBS. Facial 
nerve was most commonly involved. 
 8. Autonomic dysfunction occurred in 1/4th patients.  
9. Respiratory failure occurred in 1/3rd of patients in GBS. 
 
10. Albuminocytological dissociation was seen in majority of patients of 
GBS after 1 week. However, CSF protein level has no prognostic 
value.CSF protein level may be normal in some cases initially, repeat 
studies may show elevated protein levels. 
11. Rapid progression from onset to peak paralysis, prolonged duration of 
peak paralysis, need for ventilatory support and severity of paralysis were 
the factors associated with poor recovery from the illness. 
12. Demyelinating with secondary axonal neuropathic pattern (Mixed 
pattern) was the commonest electro physiological abnormality in this 
study. 
13. Conduction abnormalities were not similar in all the nerves studied. 
Varying severity of involvement may occur in nerves due to multi focal 
demyelination 
14. Mortality in GBS was 6% in our study. 
15. AIDP was the commonest subtype in studied population, followed by 
AMAN variant 
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                                                      PROFORMA 
 
 Name: -----------------------                                       Age / Sex: ------- yrs /  
 I. P. No: ---------------------                                       Unit: -------------  
 Date of Admission: ----------                                    Languages Spoken: --
----    
 Date of Discharge: ------------                                  Economic 
Background: - 
 Handedness: -----------------                                   Level of Education : ---
--- 
 
DIAGNOSIS: 
 
Present History:           
Time of Onset:                                       duration: 
Progression of the disease: 
Weakness of    Right UL     Left UL   Right LL    Left 
LL          
Pattern of weakness:    
Predominant proximal /   Predominant distal/   Mixed                            
Facial weakness:                                             Yes/No                              
Bulbar dysfunction:                                         Yes/No 
Other Cranial nerve dysfunction:                    Yes/No 
Neck muscle weakness:                                  Yes/No 
Respiratory difficulty:                               Yes/No 
Sensory symptoms:                                      Yes/No 
Autonomic dysfunction:                              Yes/No 
Unsteadiness of gait   :                                   Yes/No 
Preceding H/O Fever                                       (   ) 
                         Diarrhea                                (   ) 
                         Respiratory tract infection      (   ) 
                         Exanthematous illness           (   ) 
Past History: 
                        Systemic illness (HTN, DM, IHD, any other systemic  
                                                                 illness): 
 
                       Medication: 
                       Insecticidal exposure: 
                       Dog bite /snake bite: 
                       Vaccination: 
                       Other treatment History: 
Personal History: 
                               H/O venereal exposure  
                               Smoking 
                               Alcohol 
                               Diet 
Family history: 
                                          
                                              General Examination 
                
Anaemic/jaundice/clubbing 
Generalized lymphadenopathy 
Peripheral nerve thickening 
Neuro Cutaneous markers 
Alopecia/joint swelling/Rashes 
Vital Parameters: 
BP:                  Right arm                    mm of Hg 
                                             Left arm                      mm of Hg 
                Pulse:--------per min;         regular/irregular 
                Peripheral Pulse: 
               Carotids: 
                Respiration Rate & Rhythm   
                Chest wall expansion: 
                Single breath count: 
             CVS: 
             RS: 
             P/A    :                                                            Others:                                      
                         
 
 
NERVOUS SYSTEM EXAMINATION 
 
                       HMF     : 
                                       Consciousness: 
                                        Speech          :                     
                                        MMSE: 
CRANIAL NERVES EXAMINATION: 
                               Fundus 
                               Extra ocular movement 
                               Nystagmus 
                               Pupil 
                               Facial weakness: U/L                      B/L 
                               Palatal movement 
                               Gag reflex 
                               Dysphonia 
                               Neck muscle weakness 
              SPINO MOTOR SYSTEM: 
                                 Bulk   :  
                     Tone:                Right Upper Limb -   Normal / 
decreased 
                                               Right Lower Limb - Normal / 
Decreased 
                                               Left Upper Limb -    Normal / 
Decreased 
                                               Left Lower Limb -   Normal / 
Decreased                                                    
                                                                       
                                                               Right                              
Left 
                     Power:  
                               Neck                                        
                              Trunk                                 
                              Shoulder Joint   
                               Elbow   Joint 
                              Wrist Joint 
                              Hand grip  
                              Hip Joint 
                              Knee Joint 
                              Ankle Joint  
                              Toe grip            
                      Plantar     response      :                  
                      Deep Tendon Reflexes 
                                      Biceps jerk  
                                      Triceps jerk 
                                      Supinatorjerk 
                                       Knee jerk 
                                       Ankle jerk: 
       SENSORY SYSTEM   : 
                                     Pain /Touch/Temperature 
                                      Vibration sense/joint position sense 
                                      Rhomberg’s sign   
        STANCE & GAIT   :  
        CEREBELLAR SYSTEM    : 
        AUTONOMIC SYSTEM: 
         PERIPHERAL NERVE EXAMINATION: 
         Signs of meningeal irritation 
 
                                             
                                                     INVESTIGATIONS 
 
 Hb: 
 TC: ----------,                              DC: N-       L -      M -       E -     B -   
ESR ; 
Peripheral smear : 
Blood Sugar:    Random -------   Fasting-------    Postprandial------- 
(Mgms%) 
Urea: 
Creatinine : 
Sodium: 
Potassium   :   
Total Cholesterol  : 
ECG 
 
CSF analysis: 
                  Biochemistry: 
                                   Glucose 
                                    Protein 
                                    Chloride 
                                    Globulin 
                  Cell count: 
HIV Screening: 
 
Nerve conduction study:   
                                                MNC 
NERVE LATENCY 
           ( 
ms) 
AMPLITUDE
               ( 
µV) 
NCV 
(m/s) 
F 
LATENCY 
        (m/s) 
Rt Median   
Rt Ulnar       
Lt Median     
Lt Ulnar     
Rt Peroneal      
Rt Tibial     
Lt Peroneal     
Rt Tibial     
Rt Orbicularis 
oculi 
    
 Rt 
Orbicularis 
oris 
    
Lt Orbicularis 
oculi 
    
 Lt 
Orbicularis 
oris 
    
 
 
                                               SNC 
NERVE LATENCY 
           ( ms) 
AMPLITUDE 
               ( µV) 
NCV 
(m/s) 
 Rt Median    
Rt Ulnar      
Lt Median    
Lt Ulnar    
Rt Sural    
Lt Sural    
 
Inference:          Normal /Demyelinating/Axonal/Mixed  Pattern  
 
Other                : 
 
KEY TO MASTER CHART 
 
Asc.   - Ascending paralysis 
Des.   -  Descending paralysis  
 S   - Symmetrical  
 D P   - Distal paresthesia 
D W   -  Distal Weakness 
P W   -  Proximal Weakness  
Q   -  Quadriparesis 
LRTI   -  Lower Respiratory Tract infection 
URI   -  Upper Respiratory infection 
↓↓   - Depressed Reflexes    
Ð   -  Demyelinating  type 
PHT   - Postural Hypotension 
U RET  -  Urinary retention 
M-F   -  Miller Fisher Variant 
P-C-B  -  Pharyngo Cervico Brachial variant           
 
   
KEY TO MASTER CHART 
Asc.   - Ascending paralysis 
Des.   -  Descending paralysis  
 S   - Symmetrical  
 D P   - Distal paresthesia 
D W   -  Distal Weakness 
P W   -  Proximal Weakness  
Q   -  Quadriparesis 
LRTI   -  Lower Respiratory Tract infection 
URI   -  Upper Respiratory infection 
ĻĻ   - Depressed Reflexes    
Ð   -  Demyelinating  type 
PHT   - Postural Hypotension 
U RET  -  Urinary retention 
M-F   -  Miller Fisher Variant 
P-C-B  -  Pharyngo Cervico Brachial variant
